Egyszerű nézet

dc.contributor.author Szász Máté
dc.contributor.author Hajdú Mária
dc.contributor.author Pesti Natasa
dc.contributor.author Domahidy Mónika
dc.contributor.author Kristóf Katalin
dc.contributor.author Zahár Ákos
dc.contributor.author Nagy Károly
dc.contributor.author Szabó Dóra
dc.date.accessioned 2014-11-16T20:25:08Z
dc.date.available 2014-11-16T20:25:08Z
dc.date.issued 2013
dc.identifier 84890103269
dc.identifier.citation pagination=461-468; journalVolume=60; journalIssueNumber=4; journalTitle=ACTA MICROBIOLOGICA ET IMMUNOLOGICA HUNGARICA;
dc.identifier.uri http://repo.lib.semmelweis.hu//handle/123456789/556
dc.identifier.uri doi:10.1556/AMicr.60.2013.4.7
dc.description.abstract Biofilm-forming Staphylococcus epidermidis strains are common cause of the periprosthetic infection. The treatment of the periprosthetic infection is very problematic, so the prevention of these infections by an antibiotic containing prothesis could be an option for prevention.The purpose of the present study was to examine the in vitro effects of drug delivery systems (DDSs), namely Wax 1 and Wax 2 with different vancomycin content: 0.5, 1, 2 and 4 mg. In order to control the antibacterial activity of DDSs killing curve study was performed and in order to determine the antibiotic release and the antibiotic peak concentration from the DDSs biological assay was carried out.The time kill curve studies showed, that both DDSs with all vancomycin concentration decreased significantly the bacterial counts, however, Wax 2 with 4 mg vancomycin significantly decreased the bacterial count than all the other groups.The vancomycin release was the best with the highest peak concentration from DDSs with 4 mg vancomycin contain; it was significantly better than in the other groups, however, no significant difference was observed between Wax 1 and Wax 2 in this respect.These findings suggest that Wax 2 with 4 mg vancomycin content could be a potential agent for clinical use.
dc.relation.ispartof urn:issn:1217-8950
dc.title In vitro efficiency of vancomycin containing experimental drug delivery systems
dc.type Journal Article
dc.date.updated 2014-11-16T19:13:24Z
dc.language.rfc3066 en
dc.identifier.mtmt 2483179
dc.identifier.wos 000327696200007
dc.identifier.pubmed 24292089
dc.contributor.department SE/ÁOK/I/Laboratóriumi Medicina Intézet-összevont 2010 -Központi Laboratórium és Kórélettani LabMed tszcsoport
dc.contributor.department SE/ÁOK/I/Orvosi Mikrobiológiai Intézet
dc.contributor.department SE/ÁOK/K/Ortopédiai Klinika
dc.contributor.department SE/GYTK/Gyógyszerészeti Intézet
dc.contributor.institution Semmelweis Egyetem


Kapcsolódó fájlok:

A fájl jelenleg csak egyetemi IP címről érhető el.

Megtekintés/Megnyitás

Ez a rekord az alábbi gyűjteményekben szerepel:

Egyszerű nézet